AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17850609 — intervention group
Group type: EXPERIMENTAL
Intervention: both surgical modalities
Number of subjects: 10
Study 16127520 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk
Number of subjects: 225
Study 16127520 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanolin
Number of subjects: 225
Study 16127520 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 225
Study 11938346 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid A
Number of subjects: 31
Study 11938346 — intervention group
Group type: COMPARATOR
Intervention: Hydrocolloid B
Number of subjects: 31
Study 9660375 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of oral d‐fenfluramine (d‐FEN)
Number of subjects: 20
Study 9660375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7640447 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal lavage with intravenous antibiotic therapy (aminoglycoside and cephem)
Number of subjects: 53
Study 7640447 — intervention group
Group type: COMPARATOR
Intervention: Silicon tube drainage with the same systemic antibiotic therapy
Number of subjects: 53
Study 2751138 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg tetracaine with 0.2 mg epinephrine
Number of subjects: 60
Study 2751138 — intervention group
Group type: COMPARATOR
Intervention: 6 mg tetracaine alone
Number of subjects: 60
Study 2751138 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg tetracaine
Number of subjects: 60
Study 319123 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine hydrochloride (SERC)
Number of subjects: 30
Study 319123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30538075 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan co-administration
Number of subjects: 16
Study 30538075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 29401318 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 44
Study 29401318 — intervention group
Group type: COMPARATOR
Intervention: No drug (Control)
Number of subjects: 44
Study 27080379 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid morphine (100μg)
Number of subjects: 0
Study 27080379 — intervention group
Group type: COMPARATOR
Intervention: TAP block (ultrasound-guided)
Number of subjects: 0
Study 25052334 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 mg nicotine patches for four weeks before quitting, whilst smoking as normal
Number of subjects: 1786
Study 25052334 — intervention group
Group type: COMPARATOR
Intervention: Not using nicotine patches
Number of subjects: 1786
Study 22429384 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid for service choices
Number of subjects: 31
Study 22429384 — intervention group
Group type: COMPARATOR
Intervention: Control group (no decision aid)
Number of subjects: 31
Study 19726362 — intervention group
Group type: EXPERIMENTAL
Intervention: PA‐MSHA treatment in addition to neoadjuvant chemotherapy
Number of subjects: 60
Study 19726362 — intervention group
Group type: COMPARATOR
Intervention: Control group with neoadjuvant chemotherapy
Number of subjects: 60
Study 17954801 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% CHG-impregnated washcloths (Sage 2% CHG cloths)
Number of subjects: 836
Study 17954801 — intervention group
Group type: COMPARATOR
Intervention: Soap and water
Number of subjects: 836
Study 15010094 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned Codes with strategies
Number of subjects: 156
Study 15010094 — intervention group
Group type: COMPARATOR
Intervention: Planned Codes with speed
Number of subjects: 156
Study 15010094 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between scores under both conditions
Number of subjects: 156
Study 15010094 — intervention group
Group type: EXPERIMENTAL
Intervention: Effect size between the two groups
Number of subjects: 156
Study 11684980 — intervention group
Group type: COMPARATOR
Intervention: Air-filled cuff (group A)
Number of subjects: 50
Study 11684980 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline-filled cuff (group S)
Number of subjects: 50
Study 9893549 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 2 micrograms.ml‐1
Number of subjects: 45
Study 9893549 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.0625%
Number of subjects: 45
Study 9893549 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of bupivacaine and sufentanil
Number of subjects: 45
Study 9893549 — intervention group
Group type: COMPARATOR
Intervention: Plain bupivacaine
Number of subjects: 45
Study 9893549 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil alone
Number of subjects: 45
Study 8179658 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine 2 mg chewing gum
Number of subjects: 40
Study 8179658 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine 4 mg chewing gum
Number of subjects: 40
Study 8179658 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine transdermal patch
Number of subjects: 40
Study 8179658 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy (gum and patch)
Number of subjects: 40
Study 2636484 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet light treatment of 50 ml venous blood
Number of subjects: 28
Study 2636484 — intervention group
Group type: COMPARATOR
Intervention: Feigned exposure to ultraviolet rays (Control)
Number of subjects: 28
Study 8436158 — intervention group
Group type: EXPERIMENTAL
Intervention: Allomaron (allopurinol 100 mg plus benzbromarone 20 mg)
Number of subjects: 14
Study 8436158 — intervention group
Group type: COMPARATOR
Intervention: Zyloprim (allopurinol 100 mg)
Number of subjects: 14
Study 749193 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent hormonal therapy with combination chemotherapy
Number of subjects: 210
Study 749193 — intervention group
Group type: COMPARATOR
Intervention: Hormonal therapy alone (control)
Number of subjects: 210
Study 749193 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy programs (further random allocation)
Number of subjects: 210
Study 31774494 — intervention group
Group type: EXPERIMENTAL
Intervention: Training models for implementing evidence-based psychological treatment
Number of subjects: 0
Study 30418475 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg once daily
Number of subjects: 6991
Study 30418475 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily
Number of subjects: 6991
Study 28322125 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomy-specific virtual reality (VR) surgical rehearsal
Number of subjects: 16
Study 26721747 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi exercise
Number of subjects: 96
Study 26721747 — intervention group
Group type: COMPARATOR
Intervention: Low-impact exercise
Number of subjects: 96
Study 24395863 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (CIS) chemoradiotherapy
Number of subjects: 402
Study 24395863 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CIS) and tirapazamine (TPZ) chemoradiotherapy
Number of subjects: 402
Study 22623466 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with a whitening dentifrice
Number of subjects: 10
Study 22623466 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with a conventional dentifrice
Number of subjects: 10
Study 22623466 — intervention group
Group type: COMPARATOR
Intervention: Brushing without a dentifrice
Number of subjects: 10
Study 22623466 — intervention group
Group type: EXPERIMENTAL
Intervention: Brushing with both conventional and whitening dentifrices
Number of subjects: 10
Study 22623466 — intervention group
Group type: COMPARATOR
Intervention: All experimental conditions
Number of subjects: 10
Study 19632949 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 (oral fluoropyrimidine)
Number of subjects: 0
Study 19632949 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 combined with platinum compounds, irinotecan, and gemcitabine
Number of subjects: 0
Study 18158074 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg
Number of subjects: 322
Study 15349107 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue adhesive (2-octylcyanoacrylate)
Number of subjects: 133
Study 15349107 — intervention group
Group type: COMPARATOR
Intervention: Standard suture
Number of subjects: 133
Study 11906552 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant concurrent chemoradiotherapy (PCCRT)
Number of subjects: 80
Study 11906552 — intervention group
Group type: COMPARATOR
Intervention: Postoperative adjuvant radiotherapy (PRT)
Number of subjects: 80
Study 11906552 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy (PCT)
Number of subjects: 80
Study 9832218 — intervention group
Group type: EXPERIMENTAL
Intervention: Frolova primary palatoplasty technique
Number of subjects: 112
Study 9832218 — intervention group
Group type: COMPARATOR
Intervention: Furlow double-Z palatoplasty
Number of subjects: 112
Study 8031705 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg, once daily)
Number of subjects: 461
Study 8031705 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (10-40 mg, once daily)
Number of subjects: 461
Study 2590930 — intervention group
Group type: EXPERIMENTAL
Intervention: 7F catheter (hand injection)
Number of subjects: 29
Study 2590930 — intervention group
Group type: COMPARATOR
Intervention: 5F catheter (hand injection)
Number of subjects: 29
Study 2590930 — intervention group
Group type: COMPARATOR
Intervention: 5F catheter (power injection)
Number of subjects: 29
Study 2590930 — intervention group
Group type: COMPARATOR
Intervention: 5F catheter (second catheter used)
Number of subjects: 29
Study 5090759 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatological treatment plus psychiatric treatment (limited to four months)
Number of subjects: 72
Study 5090759 — intervention group
Group type: COMPARATOR
Intervention: Dermatological treatment only
Number of subjects: 72
Study 28974124 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose Dhaka regime
Number of subjects: 402
Study 28974124 — intervention group
Group type: COMPARATOR
Intervention: Loading dose only regime
Number of subjects: 402
Study 25894749 — intervention group
Group type: EXPERIMENTAL
Intervention: Early post-operative rehabilitation (EPR)
Number of subjects: 57
Study 25894749 — intervention group
Group type: COMPARATOR
Intervention: Post-operative cast immobilization (PCI)
Number of subjects: 57
Study 25459393 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and bevacizumab with capecitabine (ATX)
Number of subjects: 268
Study 25459393 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel and bevacizumab without capecitabine (AT)
Number of subjects: 268
Study 22381714 — intervention group
Group type: EXPERIMENTAL
Intervention: Avagacestat (0.3 to 800 mg)
Number of subjects: 8
Study 22381714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 20299490 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone and dutasteride
Number of subjects: 42
Study 20299490 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone and anastrozole
Number of subjects: 42
Study 20299490 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-2
Number of subjects: 42
Study 20299490 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple stimulus (GHRP-2/GHRH/l-arginine)
Number of subjects: 42
Study 20299490 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 42
Study 20299490 — intervention group
Group type: COMPARATOR
Intervention: Somatostatin (SS)
Number of subjects: 42
Study 20299490 — intervention group
Group type: COMPARATOR
Intervention: GHRH
Number of subjects: 42
Study 20299490 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 42
Study 20299490 — intervention group
Group type: EXPERIMENTAL
Intervention: 5alpha-dihydrotestosterone (DHT)
Number of subjects: 42
Study 20299490 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal visceral fat (AVF)
Number of subjects: 42
Study 18821268 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrieval opportunities (3 within-list retrieval opportunities for half the names) during multitasking in Experiment 1
Number of subjects: 293
Study 18821268 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrieval opportunities (3 additional appearances in the video without repeating names) for 8 of the 12 residents in Experiment 2
Number of subjects: 293
Study 16334715 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at points of the Du Channel
Number of subjects: 70
Study 16334715 — intervention group
Group type: COMPARATOR
Intervention: Control group (10-day decrescendo therapy of methadone only)
Number of subjects: 70
Study 12921571 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemoradiotherapy (Group A) - chemotherapy with 5‐fluorouracil and cisplatin for 2 cycles and radiotherapy of DT36 Gy/12 f/17 d followed by surgery
Number of subjects: 97
Study 12921571 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B) - operation alone
Number of subjects: 97
Study 12921571 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chemoradiotherapy (Group A)
Number of subjects: 97
Study 12921571 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 97
Study 11234740 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetanus and diphtheria toxoids adsorbed (Td)
Number of subjects: 200
Study 11234740 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 200
Study 11234740 — intervention group
Group type: COMPARATOR
Intervention: Aluminum hydroxide adjuvant (alum)
Number of subjects: 200
Study 11234740 — intervention group
Group type: EXPERIMENTAL
Intervention: VAQTA (hepatitis A vaccine)
Number of subjects: 200
Study 11234740 — intervention group
Group type: EXPERIMENTAL
Intervention: HAVRIX (hepatitis A vaccine)
Number of subjects: 200
Study 9438143 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (2 x 24 micrograms)
Number of subjects: 22
Study 9438143 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (4 x 200 micrograms)
Number of subjects: 22
Study 1623705 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional restorative treatment
Number of subjects: 52
Study 6442168 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 15
Study 31277674 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom burden
Number of subjects: 238
Study 31277674 — intervention group
Group type: EXPERIMENTAL
Intervention: Activities of daily living
Number of subjects: 238
Study 31277674 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 238
Study 31277674 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in symptom burden over a two-year period
Number of subjects: 238
Study 31277674 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression at baseline
Number of subjects: 238
Study 30785252 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve replacement
Number of subjects: 251
Study 30785252 — intervention group
Group type: COMPARATOR
Intervention: Mitral valve repair
Number of subjects: 251
Study 27687344 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 90
Study 27687344 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 25 mg
Number of subjects: 90
Study 27687344 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg
Number of subjects: 90
Study 24867312 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free latanoprost (group 1)
Number of subjects: 80
Study 24867312 — intervention group
Group type: EXPERIMENTAL
Intervention: Preserved latanoprost (group 2)
Number of subjects: 80
Study 24867312 — intervention group
Group type: EXPERIMENTAL
Intervention: Preserved timolol (group 4)
Number of subjects: 80
Study 24867312 — intervention group
Group type: COMPARATOR
Intervention: Vehicle of latanoprost or physiological buffered saline solution (group 5 and 6)
Number of subjects: 80
Study 23236031 — intervention group
Group type: EXPERIMENTAL
Intervention: Education in skin care and individual counselling
Number of subjects: 255
Study 23236031 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 255
Study 20625052 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncorrected visual acuity (VA) using a cutoff of 53 letters (6/6(-2))
Number of subjects: 4497
Study 20625052 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncorrected visual acuity (VA) using a cutoff of 45 letters (6/9.5) for myopia
Number of subjects: 4497
Study 20625052 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncorrected visual acuity (VA) using a cutoff of 57 letters (6/6(+2)) for hyperopia
Number of subjects: 4497
Study 20625052 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncorrected visual acuity (VA) using a cutoff of 55 letters (6/6) for astigmatism
Number of subjects: 4497
Study 19016201 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral cefuroxime 1 mg in 0.1 mL isotonic NaCl solution
Number of subjects: 16211
Study 19016201 — intervention group
Group type: COMPARATOR
Intervention: Topical levofloxacin 0.5%
Number of subjects: 16211
Study 19016201 — intervention group
Group type: COMPARATOR
Intervention: Clear corneal incision (CCI)
Number of subjects: 16211
Study 19016201 — intervention group
Group type: COMPARATOR
Intervention: Silicon based IOL optic material
Number of subjects: 16211
Study 19016201 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative complications
Number of subjects: 16211
Study 16261220 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicyclol 150 mg daily
Number of subjects: 31
Study 16261220 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicyclol 75 mg daily
Number of subjects: 31
Study 12021520 — intervention group
Group type: EXPERIMENTAL
Intervention: Me‐Cbl 500 microg twice/week plus FA 10 mg/day
Number of subjects: 62
Study 12021520 — intervention group
Group type: EXPERIMENTAL
Intervention: FA 10 mg/day alone
Number of subjects: 62
Study 12021520 — intervention group
Group type: COMPARATOR
Intervention: No vitamin supplementation (Control Group C)
Number of subjects: 62
Study 12021520 — intervention group
Group type: COMPARATOR
Intervention: Me‐Cbl 500 microg twice/week alone (Control Group D)
Number of subjects: 62
Study 10526812 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal wall lift
Number of subjects: 12
Study 10526812 — intervention group
Group type: COMPARATOR
Intervention: CO2 pneumoperitoneum
Number of subjects: 12
Study 8748363 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat nutrition support (15% of total calories as fat)
Number of subjects: 43
Study 8748363 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat nutrition support with fish oil
Number of subjects: 43
Study 8748363 — intervention group
Group type: COMPARATOR
Intervention: Control (35% fat)
Number of subjects: 43
Study 1835324 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (54 micrograms after the first isoetharine treatment and 36 micrograms after the second and fourth treatments)
Number of subjects: 55
Study 1835324 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen of nebulized isoetharine (0.5 mL of a 1% solution diluted to 2.0 mL with normal saline every hour)
Number of subjects: 55
Study 7258283 — intervention group
Group type: EXPERIMENTAL
Intervention: +1.25 D added to distance correction with 2 delta base-in each eye (plus-with-prism group)
Number of subjects: 232
Study 7258283 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifocals incorporating distance correction with a +1.50 D near addition (bifocal group)
Number of subjects: 232
Study 7258283 — intervention group
Group type: COMPARATOR
Intervention: No. 1 pink tint glasses for reading (placebo group)
Number of subjects: 232
Study 31113987 — intervention group
Group type: EXPERIMENTAL
Intervention: esaxerenone 1.25 mg/day
Number of subjects: 426
Study 31113987 — intervention group
Group type: EXPERIMENTAL
Intervention: esaxerenone 2.5 mg/day
Number of subjects: 426
Study 31113987 — intervention group
Group type: EXPERIMENTAL
Intervention: esaxerenone 5 mg/day
Number of subjects: 426
Study 31113987 — intervention group
Group type: EXPERIMENTAL
Intervention: eplerenone (50–100 mg/day)
Number of subjects: 426
Study 31113987 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 426
Study 26445894 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleconferencing system facilitated by trained volunteers
Number of subjects: 0
Study 26445894 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 26514931 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin 100mg/kg/day + 0.9% NSI
Number of subjects: 62
Study 26514931 — intervention group
Group type: COMPARATOR
Intervention: Placebo + 0.9% NSI
Number of subjects: 62
Study 26514931 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin + 0.9% NSI
Number of subjects: 62
Study 25073939 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity ambulatory rehabilitation programmes (≥ 3 × 1‐h weekly sessions for approximately 10 weeks)
Number of subjects: 59
Study 25073939 — intervention group
Group type: COMPARATOR
Intervention: Usual care programmes (≤ 2 × 1‐h weekly sessions)
Number of subjects: 59
Study 21084399 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment (25-75 mg daily)
Number of subjects: 274
Study 21084399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study 19953325 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Development Classroom Curriculum (SDC)
Number of subjects: 0
Study 19953325 — intervention group
Group type: EXPERIMENTAL
Intervention: School/Family/Community (SC) intervention curriculum
Number of subjects: 0
Study 19953325 — intervention group
Group type: COMPARATOR
Intervention: Health Enhancement Curriculum (HEC) attention placebo control
Number of subjects: 0
Study 17556785 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination training (CT)
Number of subjects: 0
Study 17556785 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 0
Study 17556785 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 0
Study 15191514 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole, clarithromycin and tinidazole twice‐daily
Number of subjects: 205
Study 15191514 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole, clarithromycin and tinidazole once‐daily
Number of subjects: 205
Study 15191514 — intervention group
Group type: COMPARATOR
Intervention: Placebo, clarithromycin and tinidazole once‐daily
Number of subjects: 205